A Timeline of US Biosimilar Adalimumab Launch Dates

November 11, 2018
The Center for Biosimilars Staff

AbbVie has struck agreements with multiple developers over biosimilar adalimumab, forestalling US market entry until 2023. Here's when each product could potentially reach US patients.

AbbVie has struck agreements with multiple developers over biosimilar adalimumab, forestalling US market entry until 2023. Here's when each product could reach US patients.